Universal mammalian influenza vaccine
AssigneeIowa State University Research Foundation, Inc.
InventorsDavid Verhoeven, Jessie Dorothy Trujillo, Brett Sponseller
Life of this patent
Estimating the term…
Abstract
The present invention provides vaccine or immunogenic compositions comprising novel antigens derived from the equine strain of influenza H3N8. These proteins and specific immunogenic domains are effective as primary universal influenza antigens. The disclosed vaccines or immunogenic compositions are highly effective in inducing HA specific antibodies reactive to different influenza viruses, mucosal and systemic immune responses, and cross-protection regardless of influenza virus subtypes. In some embodiments, the vaccine is cross-protective against two or more (e.g., 2, 3, 4, 5, or 6) subtypes of influenza with or without the use of an adjuvant.
Claims19
A cross-protective influenza vaccine comprising an equine H3 antigen or immunogenic fragment thereof, wherein the equine H3 antigen comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO:
- 2 and at least one glycosylated residue;
- and an adjuvant;
- wherein the vaccine is cross-protective against two or more subtypes of influenza.
A cell comprising an equine H3 antigen or immunogenic fragment thereof, wherein the equine H3 antigen comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO:
- 2 and at least one glycosylated residue, and wherein the cell is an insect cell or a yeast cell.
A pharmaceutical composition comprising a synthetic or recombinant equine H3 polypeptide comprising multiple copies of a plurality of influenza virus peptide epitopes, wherein the equine H3 polypeptide comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO:
- 2 and at least one glycosylated residue, and at least one seasonal or pandemic preparation against influenza, and containing a pharmaceutically acceptable adjuvant.
An immunogenic composition comprising an effective amount of a recombinant or synthesized equine H3 antigen or immunogenic fragment thereof, wherein the equine H3 antigen comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO:
- 2 and at least one glycosylated residue;
- an adjuvant;
- and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.